AUD 0.0
(-33.33%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 | 493.47 Thousand AUD | -88.07% |
2023 | 4.13 Million AUD | 116.95% |
2022 | 1.9 Million AUD | -55.94% |
2021 | 4.32 Million AUD | -44.72% |
2020 | 7.82 Million AUD | 33.62% |
2019 | 5.85 Million AUD | 261.72% |
2018 | 1.61 Million AUD | -21.38% |
2017 | 2.05 Million AUD | -40.87% |
2016 | 3.48 Million AUD | -24.54% |
2015 | 4.61 Million AUD | 147.66% |
2014 | 1.86 Million AUD | -61.7% |
2013 | 4.86 Million AUD | -42.49% |
2012 | 8.46 Million AUD | 219.96% |
2011 | 2.64 Million AUD | 42.35% |
2010 | 1.85 Million AUD | 74.64% |
2009 | 1.06 Million AUD | -53.08% |
2008 | 2.26 Million AUD | 49.26% |
2007 | 1.51 Million AUD | -68.45% |
2006 | 4.81 Million AUD | 98.22% |
2005 | 2.42 Million AUD | -21.89% |
2004 | 3.1 Million AUD | -47.38% |
2003 | 5.9 Million AUD | -31.55% |
2002 | 8.63 Million AUD | -15.3% |
2001 | 10.19 Million AUD | -75.86% |
2000 | 42.22 Million AUD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 FY | 493.47 Thousand AUD | -88.07% |
2024 Q2 | 2.49 Million AUD | 0.0% |
2024 Q4 | 493.47 Thousand AUD | 0.0% |
2023 Q4 | 4.13 Million AUD | 0.0% |
2023 Q2 | 6.67 Million AUD | 0.0% |
2023 FY | 4.13 Million AUD | 116.95% |
2022 Q4 | 1.9 Million AUD | 0.0% |
2022 Q2 | 2.56 Million AUD | 0.0% |
2022 FY | 1.9 Million AUD | -55.94% |
2021 FY | 4.32 Million AUD | -44.72% |
2021 Q4 | 4.32 Million AUD | 0.0% |
2021 Q2 | 5.32 Million AUD | 0.0% |
2020 Q4 | 7.82 Million AUD | 0.0% |
2020 FY | 7.82 Million AUD | 33.62% |
2020 Q2 | 8.81 Million AUD | 0.0% |
2019 Q2 | 7.11 Million AUD | 0.0% |
2019 Q4 | 5.85 Million AUD | 0.0% |
2019 FY | 5.85 Million AUD | 261.72% |
2018 Q2 | 1.65 Million AUD | 0.0% |
2018 FY | 1.61 Million AUD | -21.38% |
2018 Q4 | 1.61 Million AUD | 0.0% |
2017 Q4 | 2.05 Million AUD | 0.0% |
2017 FY | 2.05 Million AUD | -40.87% |
2017 Q2 | 1.49 Million AUD | 0.0% |
2016 Q4 | 3.48 Million AUD | 0.0% |
2016 FY | 3.48 Million AUD | -24.54% |
2016 Q2 | 3.64 Million AUD | 0.0% |
2015 FY | 4.61 Million AUD | 147.66% |
2015 Q4 | 4.61 Million AUD | 0.0% |
2015 Q2 | 3.14 Million AUD | 0.0% |
2014 Q2 | 2.22 Million AUD | 0.0% |
2014 FY | 1.86 Million AUD | -61.7% |
2014 Q4 | 1.86 Million AUD | 0.0% |
2013 Q3 | 4.86 Million AUD | -23.69% |
2013 Q2 | 6.37 Million AUD | 0.0% |
2013 FY | 4.86 Million AUD | -42.49% |
2013 Q1 | 6.37 Million AUD | -24.64% |
2013 Q4 | 4.86 Million AUD | 0.0% |
2012 Q4 | 8.46 Million AUD | 0.0% |
2012 FY | 8.46 Million AUD | 219.96% |
2011 FY | 2.64 Million AUD | 42.35% |
2011 Q4 | 2.64 Million AUD | 0.0% |
2010 FY | 1.85 Million AUD | 74.64% |
2010 Q4 | 1.85 Million AUD | 0.0% |
2009 Q4 | 1.06 Million AUD | 0.0% |
2009 FY | 1.06 Million AUD | -53.08% |
2008 Q4 | 2.26 Million AUD | 0.0% |
2008 FY | 2.26 Million AUD | 49.26% |
2007 Q4 | 1.51 Million AUD | 0.0% |
2007 FY | 1.51 Million AUD | -68.45% |
2006 FY | 4.81 Million AUD | 98.22% |
2006 Q4 | 4.81 Million AUD | 0.0% |
2005 FY | 2.42 Million AUD | -21.89% |
2005 Q4 | 2.42 Million AUD | 0.0% |
2004 Q4 | 3.1 Million AUD | 0.0% |
2004 FY | 3.1 Million AUD | -47.38% |
2003 FY | 5.9 Million AUD | -31.55% |
2003 Q4 | 5.9 Million AUD | 0.0% |
2002 FY | 8.63 Million AUD | -15.3% |
2002 Q4 | 8.63 Million AUD | 0.0% |
2001 FY | 10.19 Million AUD | -75.86% |
2001 Q4 | 10.19 Million AUD | 0.0% |
2000 FY | 42.22 Million AUD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AdAlta Limited | 5.57 Million AUD | 91.145% |
Acrux Limited | 8.96 Million AUD | 94.494% |
Amplia Therapeutics Limited | 14.84 Million AUD | 96.676% |
Biome Australia Limited | 8.27 Million AUD | 94.038% |
BTC Health Limited | 5.14 Million AUD | 90.416% |
Chimeric Therapeutics Limited | 15.27 Million AUD | 96.769% |
CSL Limited | 56.93 Billion AUD | 99.999% |
Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 99.681% |
Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 99.786% |
Noxopharm Limited | 6.78 Million AUD | 92.726% |
PharmAust Limited | 11.12 Million AUD | 95.564% |
Proteomics International Laboratories Limited | 10.87 Million AUD | 95.462% |
Prescient Therapeutics Limited | 20.39 Million AUD | 97.58% |
PYC Therapeutics Limited | 91.23 Million AUD | 99.459% |
Race Oncology Limited | 20.22 Million AUD | 97.561% |
Starpharma Holdings Limited | 36.81 Million AUD | 98.66% |
EZZ Life Science Holdings Limited | 25.55 Million AUD | 98.069% |
Botanix Pharmaceuticals Limited | 112.46 Million AUD | 99.561% |
Memphasys Limited | 12.43 Million AUD | 96.03% |
Nyrada Inc. | 5.9 Million AUD | 91.646% |
Anatara Lifesciences Ltd | 1.67 Million AUD | 70.476% |
Telix Pharmaceuticals Limited | 398.3 Million AUD | 99.876% |
Bio-Gene Technology Limited | 3.15 Million AUD | 84.382% |
Zelira Therapeutics Limited | 5.18 Million AUD | 90.48% |
Patrys Limited | 4.16 Million AUD | 88.142% |
Dimerix Limited | 32.07 Million AUD | 98.462% |
Neuren Pharmaceuticals Limited | 247.97 Million AUD | 99.801% |
Orthocell Limited | 26.61 Million AUD | 98.146% |
Imugene Limited | 151.39 Million AUD | 99.674% |
Cynata Therapeutics Limited | 8.38 Million AUD | 94.117% |
Immutep Limited | 147.44 Million AUD | 99.665% |
Arovella Therapeutics Limited | 13.28 Million AUD | 96.285% |
Alterity Therapeutics Limited | 19.22 Million AUD | 97.433% |
Nanollose Limited | 241.95 Thousand AUD | -103.957% |
Invex Therapeutics Ltd | 6.12 Million AUD | 91.937% |
NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | 90.922% |
Island Pharmaceuticals Limited | 2.56 Million AUD | 80.757% |
Radiopharm Theranostics Limited | 72.03 Million AUD | 99.315% |
Tissue Repair Ltd | 19.38 Million AUD | 97.455% |
AnteoTech Limited | 9.38 Million AUD | 94.74% |
Hexima Limited | 2.26 Million AUD | 78.251% |
Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | 98.198% |
Recce Pharmaceuticals Ltd | 6.36 Million AUD | 92.253% |
Avecho Biotechnology Limited | 7.31 Million AUD | 93.258% |
Actinogen Medical Limited | 21.31 Million AUD | 97.685% |
Immuron Limited | 15.54 Million AUD | 96.827% |
Argenica Therapeutics Limited | 16.37 Million AUD | 96.987% |